

United
States
of
America



To Promote the Progress

of Science and Useful Arts

The Director

of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this United States

Patent

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.


Andrew Lerner


DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE



US010576039B2

(12) **United States Patent**
Virno et al.

(10) **Patent No.:** US 10,576,039 B2

(45) **Date of Patent:** Mar. 3, 2020

(54) **OPHTHALMIC FORMULATION
COMPRISING CITICOLINE CARRIED BY
LIPOSOME FOR THE TREATMENT OF
GLAUCOMA**

A61K 47/36 (2006.01)
A61P 27/06 (2006.01)
A61K 9/00 (2006.01)
A61K 31/7068 (2006.01)
A61K 9/08 (2006.01)

(71) Applicant: **Omikron Italia S.r.l.**, Rome RM (IT)

(52) **U.S. CL.**

(72) Inventors: **Cristiano Virno**, Rome RM (IT);
Marco Malizia, Rome (IT)

CPC **A61K 9/127** (2013.01); **A61K 9/0048**
(2013.01); **A61K 9/08** (2013.01); **A61K**
31/7068 (2013.01); **A61K 47/18** (2013.01);
A61K 47/36 (2013.01); **A61P 27/06** (2018.01)

(73) Assignee: **Omikron Italia S.r.l.**, Rome (IT)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(58) **Field of Classification Search**

None
See application file for complete search history.

(21) Appl. No.: **16/342,261**

(56) **References Cited**

(22) PCT Filed: **Oct. 16, 2017**

FOREIGN PATENT DOCUMENTS

(86) PCT No.: **PCT/IB2017/056400**

EP 0114577 A1 * 8/1984 A61K 9/127
WO WO-2010092597 A2 * 8/2010 A61K 9/0019
WO WO-2011101802 A1 * 8/2011 A61K 9/0048

§ 371 (c)(1),

(2) Date: **Apr. 16, 2019**

* cited by examiner

(87) PCT Pub. No.: **WO2018/073720**

PCT Pub. Date: **Apr. 26, 2018**

Primary Examiner — Nannette Holloman

(74) *Attorney, Agent, or Firm* — Sterne, Kessler,
Goldstein & Fox P.L.L.C.

(65) **Prior Publication Data**

US 2019/0321292 A1 Oct. 24, 2019

(57) **ABSTRACT**

(30) **Foreign Application Priority Data**

Oct. 17, 2016 (IT) 102016000103956

The present invention relates to an ophthalmic formulation comprising citicoline and liposomes to be used in treating glaucoma. The inventors have found that the liposomes result to be particularly effective in carrying citicoline in the posterior segment of the eye (vitreous chamber) and in reaching the retina and the optic nerve head.

(51) **Int. CL**

A61K 9/127 (2006.01)

A61K 47/18 (2017.01)

21 Claims, 2 Drawing Sheets